- Open Access
Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma
- Yuka Aoki†1,
- Masanori Nojima†2,
- Hiromu Suzuki3Email author,
- Hiroshi Yasui1, 4,
- Reo Maruyama3,
- Eiichiro Yamamoto1,
- Masami Ashida3,
- Mitsuhiro Itagaki6,
- Hideki Asaoku7,
- Hiroshi Ikeda1,
- Toshiaki Hayashi1,
- Kohzoh Imai8,
- Mitsuru Mori2,
- Takashi Tokino5,
- Tadao Ishida1Email author,
- Minoru Toyota3 and
- Yasuhisa Shinomura1
© Aoki et al.; licensee BioMed Central Ltd. 2013
Received: 29 October 2012
Accepted: 22 December 2012
Published: 22 December 2012
The Erratum to this article has been published in Genome Medicine 2013 5:88
The aim of this study was to clarify the role of global hypomethylation of repetitive elements in determining the genetic and clinical features of multiple myeloma (MM).
We assessed global methylation levels using four repetitive elements (long interspersed nuclear element-1 (LINE-1), Alu Ya5, Alu Yb8, and Satellite-α) in clinical samples comprising 74 MM samples and 11 benign control samples (7 cases of monoclonal gammopathy of undetermined significance (MGUS) and 4 samples of normal plasma cells (NPC)). We also evaluated copy-number alterations using array-based comparative genomic hybridization, and performed methyl-CpG binding domain sequencing (MBD-seq).
Global levels of the repetitive-element methylation declined with the degree of malignancy of plasma cells (NPC>MGUS>MM), and there was a significant inverse correlation between the degree of genomic loss and the LINE-1 methylation levels. We identified 80 genomic loci as common breakpoints (CBPs) around commonly lost regions, which were significantly associated with increased LINE-1 densities. MBD-seq analysis revealed that average DNA-methylation levels at the CBP loci and relative methylation levels in regions with higher LINE-1 densities also declined during the development of MM. We confirmed that levels of methylation of the 5' untranslated region of respective LINE-1 loci correlated strongly with global LINE-1 methylation levels. Finally, there was a significant association between LINE-1 hypomethylation and poorer overall survival (hazard ratio 2.8, P = 0.015).
Global hypomethylation of LINE-1 is associated with the progression of and poorer prognosis for MM, possibly due to frequent copy-number loss.
Multiple myeloma (MM) is a malignant plasma-cell tumor characterized by various and frequent chromosomal aberrations. Representative examples of these aberrations are loss of chromosome 13, hyperdiploidy, and translocations involving the immunoglobulin heavy chain (IGH) locus situated at 14q32.33. Several studies have shown that these genetic changes are associated with the clinical features of MM, including its prognosis [1–7]. In addition to such genetic changes, recent studies have begun to shed light on the role of epigenetic alterations in the pathogenesis of MM. One of the earliest reports of epigenetic aberrations in MM was of DNA hypermethylation in the promoter CpG islands of p15 and p16 [8–10]. Tumor-specific hypermethylation has also been found in the promoter regions of various tumor suppressors and other tumor-related genes, including BNIP3, DAPK and RASD1, which are associated with prognosis and drug resistance in MM [11–14]. Unexpectedly, however, recent advances in genome-wide analysis revealed that the number of methylated genes declines markedly with the progression of malignant transformation of plasma cells [15, 16]. In addition, histone modifications are also involved in the pathogenesis of MM, and are associated with aberrant gene expression or important translocations such as t(4;14) [17, 18].
Global DNA hypomethylation is also known to be a common epigenetic alteration in tumor cells , and is tightly linked to hypomethylation of DNA repetitive elements . Some repetitive elements, such as long interspersed nuclear element-1 (LINE-1) and Alu, are capable of retrotransposition; that is, they are able to insert themselves into genomic sequences, which can cause genomic instabilities leading to genome-wide mutations, insertions, and deletions . Moreover, because these transpositional activities are usually silenced in association with DNA methylation, global hypomethylation is thought to promote the initiation and progression of tumorigenesis through the aberrant activation of repetitive elements . To date, there have been numerous studies demonstrating hypomethylation of repetitive elements in malignancies . In particular, hypomethylation of LINE-1 is reportedly associated with malignancy, poor prognosis, and chromosomal instability in various types of tumors [23–27].
Our aim in the present study was to clarify the role of global hypomethylation of repetitive elements in determining the genetic and clinical features of MM. To address this issue, we measured the methylation levels of four repetitive elements, and assessed their association with genome-wide copy-number alterations. This integrative analysis of the genetic, epigenetic, and clinical characteristics of MM enabled us to discover a strong association between LINE-1 hypomethylation and copy-number loss and poor prognosis in patients with MM.
Materials and Methods
This study was approved by the institutional review board at Sapporo Medical University (Ethics Committee) and conforms to the tenets of the Declaration of Helsinki. informed consent was obtained prior to sample collection.
Patients and sample preparation
Bone-marrow aspirates were collected between 2007 and 2010 at the Department of Hematology (Hiroshima Red Cross and Atomic-Bomb Survivors Hospital) and in the 1st Department of Internal Medicine (Sapporo Medical University Hospital) from patients with MM (n = 74), patients with monoclonal gammopathy of undetermined significance (MGUS, n = 7), and patients with non-plasma-cell tumors with normal plasma cells (NPC, n = 4).
We isolated mononuclear cells from the samples using density-gradient separation (Ficoll-Paque; StemCell Technologies Inc., Vancouver, Canada), and then separated the CD138-positive cells using CD138 polymer particles (CD138 MicroBeads; Miltenyi Biotec GmBH, Gladbach, Germany) to isolate the plasma cells. Finally, we extracted the genomic DNA from the CD138-positive cells (QIAamp DNA Blood Mini Kit; Qiagen Inc., Valencia, CA, USA).
Bisulfite conversion of genomic DNA was carried out (EpiTect Bisulfite Kit; Qiagen Inc.). We then used PCR to amplify sequences containing CpG sites in the promoter regions of LINE-1, Alu Yb8, Alu Ya5, and Satellite-α on chromosome 1 (Sat-α), as described previously . The biotinylated PCR products were purified, made single-stranded, and used as templates in a pyrosequencing reaction according to the manufacturer's instructions (Qiagen Inc.). Briefly, the PCR products were bound to streptavidin-conjugated beads (Streptavidin Sepharose HP Beads; Amersham Biosciences Inc., Piscataway, NJ, USA), and were then purified, washed, and denatured with 0.2 mol/L NaOH solution. After addition of 0.3 μmol/L sequencing primer to the purified PCR products, pyrosequencing was carried out using an appropriate system (PSQ96MA) and software (Pyro Q-CpG) (both Biotage AB, Uppsala, Sweden). The primer sequences used in this study are listed in Additional file 1, Table S1.
Array comparative genomic hybridization
Array comparative genomic hybridization (aCGH) analysis was performed according to the manufacturer's instructions (Agilent Technologies Inc., Wilmington, DE, USA). We first used the restriction enzymes AluI and RsaI to digest 500 ng each of genomic DNA from 67 MM and 6 MGUS samples as well as an aliquot of gender-matched reference DNA (Promega Corp., Madison, WI, USA). We then labeled (Genomic DNA Enzymatic Labeling Kit; Agilent Technologies) the sample and reference DNAs with Cy5 and Cy3, respectively. The labeled DNA was mixed with 25 μg of Cot-1 DNA (Invitrogen), denatured at 95°C for 3 minutes, and incubated at 37°C for 30 minutes. The probe mixture was then hybridized for 40 hours at 65°C (G4450A; SurePrint G3 Human CGH Microarray Kit 8x60K; Agilent Technologies). After washing the array, it was scanned (G2565BA Microarray Scanner; Agilent Technologies) and the fluorescent signals were acquired (Feature Extraction Software; Agilent Technologies). The ADM-2 algorithm included in Genomic Workbench Software (version 6.0; Agilent Technologies) was used to identify copy-number alterations (reference genome: hg 18, threshold = 5.0, minimum number of probes = 3 continuous probes, minimum average of log2 ratio = 0.5). Because the sex chromosomes are strictly controlled through epigenetic mechanisms, they were excluded from this analysis. The Gene Expression Omnibus accession number of the microarray data is GSE33685.
Methyl-CpG binding domain sequencing
High-throughput sequencing of methylated DNA enriched with methyl-CpG binding domain (MBD) protein (MBD-seq) was performed as follows. Methylated DNA was enriched from 0.5 to 2 µg of genomic DNA obtained from 9 MM, 3 MGUS and 3 NPC specimens (MethylaMiner™Methylated DNA Enrichment Kit; Life Technologies Corp., Carlsbad, CA, USA) according to the manufacturer's instructions. We then prepared a fragment library (SOLiD Fragment Library Construction Kit; Life Technologies) and performed deep sequencing (SOLiD™3 Plus system; Life Technologies). The sequenced reads were mapped onto the human genome (UCSC hg18) using Bowtie software .
The number of sequence reads between a pair of sequential aCGH probe sets was counted and then divided by the distance between the probes to obtain the average number of sequence reads per nucleotide. To exclude bias due to intragenomic variation in mapping efficiency, the number of average sequence reads was normalized to the number of sequence reads obtained from control (input) samples to which MBD protein was not applied. We defined that value as the average DNA methylation level. In addition, to exclude bias due to interchromosomal variation caused by copy-number aberrations, the average DNA-methylation levels were normalized to the copy numbers of the respective loci obtained from aCGH. Because the normalized average methylation-level data followed a log-normal distribution, they were log-transposed and statistically standardized.
Differences in mean methylation levels between groups were tested using t-tests (for two groups) or ANOVA with a post hoc Games-Howell test (for more than two groups). Pearson's correlation coefficients were calculated to evaluate the correlations between two continuous variables. For correlation analysis, log transformation was performed to normalize the number of aCGH probes. Unsupervised hierarchical clustering of the samples using the aCGH results was performed(Cluster 3.0,; originally developed by Michael Eisen, Stanford University). Densities of the repetitive elements were compared using the Mantel-Haenszel test for linear associations. The linear trend of the methylation levels with categorical values were tested using polynomial contrast in general linear models. To evaluate the overall survival (OS) of patients with MM, Kaplan-Meier curves were constructed and evaluated using the log-rank test, and Cox regression was performed. Values of P<0.05 were considered statistically significant. Because most variables in this study were inter-associated (e.g., chromosomal aberration status), we did not perform the adjustment for multiple comparisons. All statistical analyses were performed using SPSS Statistics software (version 20 IBM; SPSS Inc., Chicago, IL, USA).
Hypomethylation of repetitive elements in MM and MGUS
Association between repetitive-element methylation and chromosomal aberrations
To quantify the degree of copy-number aberration, we determined for each tumor the number of aCGH probes within copy-number gain or loss regions, and compared that to the level of LINE-1 methylation. In this analysis, the probe number was used as a surrogate for the degree of global genomic alteration. Notably, we found a strong inverse correlation between the numbers of losses found by the probes and the LINE-1 methylation levels, whereas the gains did not show this tendency (Figure 3C). Similar results were obtained for other repetitive elements, but the correlations were weaker than those for LINE-1 (see Additional file 5, Figure S2E).
LINE-1 density and genomic vulnerability to global hypomethylation
List of common breakpoints
(per 100,000 bp)
Break frequency, %
Break frequency, %
In addition, although the involvement of physiological class-switch rearrangements could not be ruled out in our experiments, we noted several CBPs within the IGH locus at 14q32.33, which is known to be a scaffold for distinctive translocations in MM (e.g., t(11;14)(q13;q32) and t(4;14)(p16;q32)). Consistent with the findings described above, we observed significantly greater LINE-1 density in the IGH locus than in the neighboring genomic regions (P < 0.001) (see Additional file 6, Figures S3B,C).
Lower methylation levels at common breakpoints and LINE-1-dense regions in MM
We next stratified genomic regions according to their LINE-1 densities, and calculated the average methylation levels in the respective categories. We observed an inverse relationship between methylation levels and LINE-1 densities in MM, whereas methylation levels and LINE-1 densities were positively correlated in MGUS, and this tendency was even clearer in NPC (Figure 4B). These observations again support our hypothesis that methylation levels in LINE-1-enriched regions decline during the development of MM.
When we assessed the methylation levels at breakpoints in respective samples, we observed that all but one MM sample showed reduced methylation at the sample-specific breakpoints, which is not consistent with the observations summarized above (Figure 4C, MM3 and MM7). Interestingly, however, one sample (MM4) showed frequent genomic breaks (133 breakpoints) with higher methylation levels at the breakpoints (Figure 4C). We also found that the sample-specific breakpoints in MM4 were not associated with higher LINE-1 density, which was different from the majority of MM samples (Figure 4D). Collectively, our results suggest that higher LINE-1 densities and hypomethylation are significantly associated with breakpoints in the majority of MM samples, while a subset of samples do not follow this pattern (the small number of exceptional samples are shown in Figure 3C,E).
Locus-specific LINE-1 methylation correlates with global LINE-1 methylation
To confirm that the global methylation levels determined by our bisulfite pyrosequencing truly reflect the methylation status at the respective loci, we next performed locus-specific bisulfite pyrosequencing at selected LINE-1 loci. We first analyzed the 5' untranslated region (UTR) of a LINE-1 sequence in one of the CBPs on chromosome 12p13.2; genomic alterations are commonly observed in this area in hematological malignancies (see Additional file 7, Figures S4A, B; see Additional file 2, Table S2). In addition, we analyzed a second 5' UTR of a LINE-1 in a non-breakpoint region on chromosome 12q21.1. In both assessments, we observed a significant positive correlation between local and global LINE-1 methylation levels (Figure 4E), and also between the two local LINE-1 methylation levels (see Additional file 7 Figure S4C). By contrast, methylation levels in the gene body region of LINE-1 (ORF2) at 12p12.3 were consistently high in most samples, and did not correlate with global LINE-1 methylation levels (Figure 4F). Because global methylation was also assessed at the 5' UTR of LINE-1 (see Additional file 4, Figure S1A), these results confirmed that global hypomethylation during the development of MM is closely associated with reduced methylation levels at respective LINE-1 loci.
Association of LINE-1 hypomethylation with a poor prognosis in MM
We also found that global LINE-1 methylation level tended to be inversely correlated with stage according to the International Staging System (ISS) (P for trend = 0.078; ISS stage 1, 44.7%; stage 2, 41.6%; stage 3, 38.4%). To exclude any effect of different clinical stages for patients, we stratified the samples into two groups: those with ISS stage 1 MM, and those with stage 2 or 3 MM. Even after adjusting for clinical stage, patients with LINE-1 hypomethylation showed significantly poorer OS (Figure 5B). In addition, after adjustment for other prognostic factors, including age, sex, ISS, and loss of chromosome 13 (with stratification by center), LINE-1 hypomethylation was still independently associated with a poor prognosis (hazard ratio = 3.9, P = 0.028; Additional file 8, Figure S5B). We also evaluated the associations of Alu Yb8, Alu Ya5, and Sat-α hypomethylation with prognosis, but these were not as strongly associated as LINE-1 hypomethylation (see Additional file 8, Figure S5C). Although a weak association was observed between Alu Ya5 hypomethylation and shorter OS, it was not statistically significant after adjustment for the other prognostic factors (hazard ratio = 1.7, P = 0.430).
In this study, we analyzed the DNA methylation of several representative repetitive elements: LINE-1, Alu, and Sat-α. LINE-1 is an abundant retrotransposon that makes up approximately 20% of the mammalian genome. It encodes a reverse transcriptase and is able to amplify and transpose itself within the genome. Alu is one of the short interspersed elements that comprise approximately 10% of the total DNA. Alu does not encode a functional protein, but depends on the machinery of active LINE-1 for transposition [30, 31]. Sat-α is a member of the tandemly repeated sequence family, members of which are located at the centromeres of all primate chromosomes . Their presence and spread cause several inherited diseases through the induction of genomic diversity [21, 33]. To avoid their inappropriate activation, transcription of repetitive elements is regulated by epigenetic mechanisms, including DNA methylation . Dysregulation of repetitive elements, especially LINE-1, due to hypomethylation, has recently been observed in various tumors [24–27, 34–37]. Moreover, insertion of LINE-1 leads to activation of several oncogenes [38, 39]. We found strong positive correlations between methylation levels of the all repetitive elements analyzed including local-specific LINE-1 (Figure 1A; see Additional file 3, Table S3, Figure 4E), which suggests the existence of a key factor inducing global hypomethylation of repetitive elements.
Methylation within the promoter regions of protein-coding genes has been found to be generally lower in MM than MGUS or NPC [15, 16], and it declines progressively during malignant progression in plasma cells. In the present study, we found a similar decline in the methylation of repetitive elements in MGUS and MM samples. Bollati et al. also observed lower levels of repetitive-element methylation in MM, but they did not analyze methylation levels in MGUS . Reduced methylation of repetitive elements has also been reported in precancerous lesions in various organs [41, 42], suggesting that global hypomethylation is an early event during tumorigenesis in a number of malignancies. Although methylation of repetitive elements was generally down-regulated in MM compared with NPC, there was substantial case-to-case variability, and the level of methylation, especially of LINE-1, was strongly associated with the degree of copy-number loss and genomic breaks. Similar findings have been reported for other types of malignancy, suggesting that global hypomethylation is associated with chromosomal instability [26, 27, 35, 36]. Consistent with that idea, recent evidence suggests that hypomethylation-induced activation of repetitive elements is directly associated with the chromosomal instability seen in cancer [21, 38, 39, 43, 44]. In the context of those earlier reports, our findings indicate that, in malignant cells, LINE-1 may be more active and exhibit a greater potential to induce genomic alterations than other repetitive elements.
We found that LINE-1 density was greater at the 80 CBPs than elsewhere, which suggests that hypomethylation of LINE-1 may be an important factor affecting genomic breaks. For example, the 14q32.33 locus, which exhibits frequent chromosomal translocations and rearrangements in MM and shows very high LINE-1 density, is a site that exhibits possible vulnerability in MM. Conceptually similar to the CBPs described in this study, common fragile sites (CFSs) are highly unstable regions of the genome . Our data indicate that one well-known CFS, FRA6E/PARK2, is located at chromosome 6q26 , and the surrounding area is also a CBP in MM. A number of CFSs are reportedly located in regions in which there is a high density of both repetitive elements and CBPs [47, 48]. In addition, genomic loci at 12p13, where we investigated local LINE-1 methylation levels and which is a CBP, are frequently deleted, and are associated with a poor prognosis in MM . Chromosomal aberrations at 12p13 have also been reported in other types of hematological malignancy . We also identified two CBPs at 13q14, a critical region that is often deleted in MM and other lymphoid disorders, and in which enrichment of LINE-1 and repetitive elements has been reported .
Our results demonstrate that DNA-methylation levels at CBPs and regions with high LINE-1 densities decline during the development of MM. Detailed analysis of selected LINE-1 loci revealed that reductions in methylation within the 5' UTR, but not the gene body region, were significantly associated with global hypomethylation. These results indicate that hypomethylation in the 5' UTR of LINE-1 at CBP regions is deeply involved in the development of MM. However, our findings may not support a simple hypothesis that hypomethylation at LINE-1 loci is a determinant of genomic vulnerability at that position, because methylation levels of both CBP-associated and CBP-independent LINE-1 loci positively correlated with global methylation. Collectively, our results suggest that both higher LINE-1 density and hypomethylation in the 5' UTR may be critical factors inducing genomic vulnerability in MM. By contrast, we also observed that a small number of MM cases exhibited frequent genomic breaks, despite relatively high global LINE-1 methylation levels. These cases may be indicative of an underlying mechanism other than LINE-1 hypomethylation, and further study will be needed to understand the complexity of genomic vulnerability in malignant cells.
In addition to LINE-1, Sat-α is reportedly hypomethylated and transcriptionally active in various tumors [23, 52]. Although we found the strongest correlation between copy-number aberrations and LINE-1 hypomethylation, further investigation of the significance of other repetitive elements is needed. We observed a stronger association between repetitive-element methylation and chromosomal aberrations than did Bollati et al. in their earlier study . This may be attributable to differences in the technologies used to detect copy-number alterations; whereas we performed aCGH that was specialized for comprehensive and sensitive genomic analysis, Bollati et al. used fluorescence in situ hybridization to detect specific chromosomal aberrations.
Although we demonstrated a novel association between the density and hypomethylation of LINE-1 and genomic alterations in MM, there are several limitations to this study. First, the number of benign control samples was small, and as a result, the statistical power was not sufficient to find significant associations. Second, because we could not obtain control samples of normal DNA from the patients with MM, our results may have been partially influenced by inter-individual copy-number variations. In addition, as described above, we could not rule out the involvement of physiological class-switch rearrangements at the IGH locus. Third, and most importantly, because a longitudinal study was not performed to analyze the molecular changes during the development and progression of MM, the direct causal relationship between LINE-1 hypomethylation and genomic vulnerability remains to be validated in a future functional study.
Despite the aforementioned limitations, we found that LINE-1 hypomethylation is associated with a poor prognosis in MM. Even after stratification and adjustment for several confounders, the association remained statistically significant, suggesting LINE-1 hypomethylation as an independent prognostic factor. Moreover, our findings are consistent with similar results obtained in other malignancies, and is supported by several reports in which a poorer prognosis was observed in MM with non-hyperdiploidy [23, 25, 36, 37].. Our data suggest that non-hyperdiploidy, which is indicative of genomic and chromosomal loss, is associated with LINE-1 hypomethylation .
Our findings suggest that global hypomethylation of repetitive elements may increase the malignant potential of myeloma cells by inducing broad copy-number losses. In particular, LINE-1 is a probable contributing factor for chromosomal aberrations and the progression of MM under conditions of global hypomethylation. Our results also indicate that clinical management should include analysis of repetitive-element methylation. For further investigation, we plan a detailed functional study to clarify the cause of global hypomethylation and the precise mechanism of hypomethylation-mediated genomic breaks in MM.
We thank Dr William F. Goldman for editing the manuscript. Financial support was received from the following. Grant support: grants-in-aid for Scientific Research from the Japan Society for Promotion of Science (MN, HS, HY, KI, MM, TMT and YS), the Award in Aki's Memory from the Internal Myeloma Foundation Japan and Ono Cancer Research Fund (HY), the A3 Foresight Program from the Japan Society for Promotion of Science (HS), a grant-in-aid for the Third-term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labor, and Welfare, Japan (MT, HS).
- Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RK, Konn ZJ, Stockley DM, Gregory WM, Davies FE, Ross FM, Morgan GJ: A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010, 116: e56-65. 10.1182/blood-2010-04-279596.PubMedView ArticleGoogle Scholar
- Avet Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, et al: Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007, 109: 3489-3495. 10.1182/blood-2006-08-040410.PubMedView ArticleGoogle Scholar
- Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD: The molecular classification of multiple myeloma. Blood. 2006, 108: 2020-2028. 10.1182/blood-2005-11-013458.PubMedPubMed CentralView ArticleGoogle Scholar
- Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R: Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002, 99: 2185-2191. 10.1182/blood.V99.6.2185.PubMedView ArticleGoogle Scholar
- Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD, Brennan C, Depinho RA: High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006, 9: 313-325. 10.1016/j.ccr.2006.03.019.PubMedView ArticleGoogle Scholar
- Yasui H, Hideshima T, Richardson PG, Anderson KC: Recent advances in the treatment of multiple myeloma. Curr Pharm Biotechnol. 2006, 7: 381-393. 10.2174/138920106778521569.PubMedView ArticleGoogle Scholar
- Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC: Advances in biology of multiple myeloma: clinical applications:. Blood. 2004, 104: 607-618. 10.1182/blood-2004-01-0037.PubMedView ArticleGoogle Scholar
- Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP: Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood. 1997, 89: 2500-2506.PubMedGoogle Scholar
- Guillerm G, Gyan E, Wolowiec D, Facon T, Avet-Loiseau H, Kuliczkowski K, Bauters F, Fenaux P, Quesnel B: p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood. 2001, 98: 244-246. 10.1182/blood.V98.1.244.PubMedView ArticleGoogle Scholar
- Gonzalez-Paz N, Chang WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R: Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood. 2007, 109: 1228-1232.PubMedView ArticleGoogle Scholar
- Murai M, Toyota M, Satoh A, Suzuki H, Akino K, Mita H, Sasaki Y, Ishida T, Shen L, Garcia-Manero G, Issa JP, Hinoda Y, Tokino T, Imai K: Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer. 2005, 92: 1165-1172. 10.1038/sj.bjc.6602422.PubMedPubMed CentralView ArticleGoogle Scholar
- Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, Bilban M, Zielinski CC, Drach J, Zochbauer Muller S: Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res. 2008, 68: 44-54. 10.1158/0008-5472.CAN-07-2531.PubMedView ArticleGoogle Scholar
- Nojima M, Maruyama R, Yasui H, Suzuki H, Maruyama Y, Tarasawa I, Sasaki Y, Asaoku H, Sakai H, Hayashi T, Mori M, Imai K, Tokino T, Ishida T, Toyota M, Shinomura Y: Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res. 2009, 15: 4356-4364. 10.1158/1078-0432.CCR-08-3336.PubMedView ArticleGoogle Scholar
- Braggio E, Maiolino A, Gouveia ME, Magalhaes R, Souto Filho JT, Garnica M, Nucci M, Renault IZ: Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol. 2010, 91: 87-96. 10.1007/s12185-009-0459-2.PubMedView ArticleGoogle Scholar
- Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, Carpten J: DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res. 2010, 70: 6934-6944. 10.1158/0008-5472.CAN-10-0282.PubMedView ArticleGoogle Scholar
- Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ: Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011, 117: 553-562. 10.1182/blood-2010-04-279539.PubMedView ArticleGoogle Scholar
- Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, Heffner A, Will C, Lamy L, Staudt LM, Levens DL, Kelleher NL, Licht JD: The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 2011, 117: 211-220. 10.1182/blood-2010-07-298349.PubMedPubMed CentralView ArticleGoogle Scholar
- De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg Wiklund H, Vanderkerken K: IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood. 2010, 115: 2430-2440. 10.1182/blood-2009-07-232801.PubMedView ArticleGoogle Scholar
- Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983, 301: 89-92. 10.1038/301089a0.PubMedView ArticleGoogle Scholar
- Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M, Laird PW: Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005, 33: 6823-6836. 10.1093/nar/gki987.PubMedPubMed CentralView ArticleGoogle Scholar
- Cordaux R, Batzer MA: The impact of retrotransposons on human genome evolution. Nat Rev Genet. 2009, 10: 691-703. 10.1038/nrg2640.PubMedPubMed CentralView ArticleGoogle Scholar
- Choi SH, Worswick S, Byun HM, Shear T, Soussa JC, Wolff EM, Douer D, Garcia-Manero G, Liang G, Yang AS: Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer. 2009, 125: 723-729. 10.1002/ijc.24384.PubMedPubMed CentralView ArticleGoogle Scholar
- Widschwendter M, Jiang G, Woods C, Muller HM, Fiegl H, Goebel G, Marth C, Muller-Holzner E, Zeimet AG, Laird PW, Ehrlich M: DNA hypomethylation and ovarian cancer biology. Cancer Res. 2004, 64: 4472-4480. 10.1158/0008-5472.CAN-04-0238.PubMedView ArticleGoogle Scholar
- Jackson K, Yu MC, Arakawa K, Fiala E, Youn B, Fiegl H, Muller-Holzner E, Widschwendter M, Ehrlich M: DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther. 2004, 3: 1225-1231. 10.4161/cbt.3.12.1222.PubMedView ArticleGoogle Scholar
- Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS: A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008, 100: 1734-1738. 10.1093/jnci/djn359.PubMedPubMed CentralView ArticleGoogle Scholar
- Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, Kotsinas A, Gorgoulis V, Field JK, Liloglou T: Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer. 2009, 124: 81-87. 10.1002/ijc.23849.PubMedView ArticleGoogle Scholar
- Igarashi S, Suzuki H, Niinuma T, Shimizu H, Nojima M, Iwaki H, Nobuoka T, Nishida T, Miyazaki Y, Takamaru H, Yamamoto E, Yamamoto H, Tokino T, Hasegawa T, Hirata K, Imai K, Toyota M, Shinomura Y: A novel correlation between LINE-1 hypomethylation and the malignancy of gastrointestinal stromal tumors. Clin Cancer Res. 2010, 16: 5114-5123. 10.1158/1078-0432.CCR-10-0581.PubMedView ArticleGoogle Scholar
- Johns Hopkins University. Bowtie: An ultrafast, memory-efficient short read aligner. [http://bowtie-bio.sourceforge.net/index.shtml]
- University of California Santa Cruz: UCSC Genome Bioinformatics. [http://genome.ucsc.edu/]
- Bock C, Tomazou EM, Brinkman AB, Muller F, Simmer F, Gu H, Jager N, Gnirke A, Stunnenberg HG, Meissner A: Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol. 2010, 28: 1106-1114. 10.1038/nbt.1681.PubMedPubMed CentralView ArticleGoogle Scholar
- Wallace N, Wagstaff BJ, Deininger PL, Roy-Engel AM: LINE-1 ORF1 protein enhances Alu SINE Retrotransposition. Gene. 2008, 419: 1-6. 10.1016/j.gene.2008.04.007.PubMedPubMed CentralView ArticleGoogle Scholar
- She X, Horvath JE, Jiang Z, Liu G, Furey TS, Christ L, Clark R, Graves T, Gulden CL, Alkan C, Bailey JA, Sahinalp C, Rocchi M, Haussler D, Wilson RK, Miller W, Schwartz S, Eichler EE: The structure and evolution of centromeric transition regions within the human genome. Nature. 2004, 430: 857-864. 10.1038/nature02806.PubMedView ArticleGoogle Scholar
- Batzer MA, Deininger PL: Alu repeats and human genomic diversity. Nat Rev Genet. 2002, 3: 370-379. 10.1038/nrg798.PubMedView ArticleGoogle Scholar
- Baba Y, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, Schernhammer ES, Hunter DJ, Giovannucci EL, Fuchs CS, Ogino S: Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer. 2010, 9: 125-10.1186/1476-4598-9-125.PubMedPubMed CentralView ArticleGoogle Scholar
- Estecio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R, Jelinek J, Yang AS, Yan PS, Huang TH, Tajara EH, Issa JP: LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One. 2007, 2: e399-10.1371/journal.pone.0000399.PubMedPubMed CentralView ArticleGoogle Scholar
- Zeimet AG, Fiegl H, Goebel G, Kopp F, Allasia C, Reimer D, Steppan I, Mueller-Holzner E, Ehrlich M, Marth C: DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer. Gynecol Oncol. 2011, 121: 24-31. 10.1016/j.ygyno.2010.12.332.PubMedPubMed CentralView ArticleGoogle Scholar
- Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T: The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS One. 2011, 6: e23332-10.1371/journal.pone.0023332.PubMedPubMed CentralView ArticleGoogle Scholar
- Weber B, Kimhi S, Howard G, Eden A, Lyko F: Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription. Oncogene. 2010, 29: 5775-5784. 10.1038/onc.2010.227.PubMedView ArticleGoogle Scholar
- Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD, Yang AS, Jones PA, Liang G: Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 2010, 6: e1000917-10.1371/journal.pgen.1000917.PubMedPubMed CentralView ArticleGoogle Scholar
- Bollati V, Fabris S, Pegoraro V, Ronchetti D, Mosca L, Deliliers GL, Motta V, Bertazzi PA, Baccarelli A, Neri A: Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis. 2009, 30: 1330-1335. 10.1093/carcin/bgp149.PubMedView ArticleGoogle Scholar
- Yoshida T, Yamashita S, Takamura-Enya T, Niwa T, Ando T, Enomoto S, Maekita T, Nakazawa K, Tatematsu M, Ichinose M, Ushijima T: Alu and Satalpha hypomethylation in Helicobacter pylori-infected gastric mucosae. Int J Cancer. 2011, 128: 33-39. 10.1002/ijc.25534.PubMedView ArticleGoogle Scholar
- Yamamoto E, Toyota M, Suzuki H, Kondo Y, Sanomura T, Murayama Y, Ohe-Toyota M, Maruyama R, Nojima M, Ashida M, Fujii K, Sasaki Y, Hayashi N, Mori M, Imai K, Tokino T, Shinomura Y: LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis. Cancer Epidemiol Biomarkers Prev. 2008, 17: 2555-2564. 10.1158/1055-9965.EPI-08-0112.PubMedView ArticleGoogle Scholar
- Han JS, Szak ST, Boeke JD: Transcriptional disruption by the L1 retrotransposon and implications for mammalian transcriptomes. Nature. 2004, 429: 268-274. 10.1038/nature02536.PubMedView ArticleGoogle Scholar
- Iskow RC, McCabe MT, Mills RE, Torene S, Pittard WS, Neuwald AF, Van Meir EG, Vertino PM, Devine SE: Natural mutagenesis of human genomes by endogenous retrotransposons. Cell. 2010, 141: 1253-1261. 10.1016/j.cell.2010.05.020.PubMedPubMed CentralView ArticleGoogle Scholar
- Glover TW, Berger C, Coyle J, Echo B: DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet. 1984, 67: 136-142. 10.1007/BF00272988.PubMedView ArticleGoogle Scholar
- Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, D'Andrilli G, Scambia G, Picchio MC, Alder H, Godwin AK, Croce CM: Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA. 2003, 100: 5956-5961. 10.1073/pnas.0931262100.PubMedPubMed CentralView ArticleGoogle Scholar
- Jiang Y, Lucas I, Young DJ, Davis EM, Karrison T, Rest JS, Le Beau MM: Common fragile sites are characterized by histone hypoacetylation. Hum Mol Genet. 2009, 18: 4501-4512. 10.1093/hmg/ddp410.PubMedPubMed CentralView ArticleGoogle Scholar
- Morelli C, Karayianni E, Magnanini C, Mungall AJ, Thorland E, Negrini M, Smith DI, Barbanti Brodano G: Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene. 2002, 21: 7266-7276. 10.1038/sj.onc.1205573.PubMedView ArticleGoogle Scholar
- Avet Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL, Attal M, Marit G, Mathiot C, Facon T, Moreau P, Anderson KC, Campion L, Munshi NC, Minvielle S: Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009, 27: 4585-4590. 10.1200/JCO.2008.20.6136.PubMedPubMed CentralView ArticleGoogle Scholar
- Saez B, Martin Subero JI, Largo C, Martin MC, Odero MD, Prosper F, Siebert R, Calasanz MJ, Cigudosa JC: Identification of recurrent chromosomal breakpoints in multiple myeloma with complex karyotypes by combined G-banding, spectral karyotyping, and fluorescence in situ hybridization analyses. Cancer Genet Cytogenet. 2006, 169: 143-149. 10.1016/j.cancergencyto.2006.04.008.PubMedView ArticleGoogle Scholar
- Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, Kipps TJ, Croce CM: Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res. 2001, 61: 6640-6648.PubMedGoogle Scholar
- Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ, Contino G, Deshpande V, Iafrate AJ, Letovsky S, Rivera MN, Bardeesy N, Maheswaran S, Haber DA: Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science. 2011, 331: 593-596. 10.1126/science.1200801.PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.